# Bicara Therapeutics Inc. (BCAX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $23.17, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bicara Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.3×**. The shares trade at 3.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.8%** (5-yr avg -18.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -34.4%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 37.8%**. Earnings per share rose 37.8%.

## Financial health
- **Current ratio: 14.58** (quick 14.58). Current assets cover the next year's liabilities 14.58 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Bicara Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Bicara Therapeutics Inc.; the consensus is buy, with an average price target of $33.50 (+45% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 92.1%** (YTD 37.7%, 3-mo 15.8%). The shares are up 92.1% over twelve months including dividends.
- **From 52-week high: -25.2%** (125.1% above the low). Trading 25% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 0.97** (volatility 61%). Beta of 0.97 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BCAX · Page: https://foliofundamentals.com/stocks/bcax

Not investment advice.